MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by AYLING, J. E.
Right arrow Articles by KUN, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by AYLING, J. E.
Right arrow Articles by KUN, E.

Molecular Pharmacology, Vol 1, 255-265, Copyright © 1965 by the American Society for Pharmacology and Experimental Therapeutics

Studies with Specific Enzyme Inhibitors

X. Mechanism of Action of L-(+)-beta-Monofluorolactate on Crystalline Heart Muscle Lactate Dehydrogenase

J. E. AYLING 1 and ERNEST KUN 1

1 Departments of Pharmacology and Biochemistry, School of Medicine, and the Cardiovascular Research Institute, University of California, San Francisco, California

The L-(+) stereoisomer of beta-monofluorolactic acid is a specific inhibitor of lactic acid dehydrogenase. The inhibition is competitive with respect to L-(+)-lactate, uncompetitive with DPN and pyruvate, and noncompetitive with DPNH. Kinetic analyses of substrate pairs in the presence of fluorolactate revealed that Ki with respect to DPN is a linear function of the concentration of lactate, while Ki with respect to lactate is directly proportional to the reciprocal of the concentration of DPN. In the reverse direction Ki with respect to pyruvate is independent of the concentration of DPNH, and Ki with respect to DPNH is a linear function of the reciprocal of the concentration of pyruvate. Fluorolactate in the forward reaction can combine only with the enzyme-DPN complex, while in the reverse direction the prerequisite for inhibition is the formation of an enzyme—pyruvate—DPNH complex.

Note:
ACKNOWLEDGMENTS Supported by grants of the National Science Foundation (GB 3488) and the U.S. Public Health Service (R01-CA-07955-01 and R01-HD-01239-09). The technical assistance of Mrs. Charlotte Schmid is gratefully acknowledged.

Submitted on September 2, 1965




This article has been cited by other articles:


Home page
 ScienceHome page
P. Goldman
The Carbon-Fluorine Bond in Compounds of Biological Interest
Science, June 6, 1969; 164(3884): 1123 - 1130.
[PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1965 by the American Society for Pharmacology and Experimental Therapeutics